Published in Medical Letter on the CDC and FDA, April 8th, 2007
Approved earlier this month by the U.S. Food & Drug Administration, the BRU(TM) uses the Z800 3DVisor to selectively stimulate the neural processes involved in the vestibular compensation mechanisms. The BRU enables the physician to assess the extent of the problem and treat it. Assessment involves analyzing a patients a series of postures as he or she receives a specific sensory...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.